期刊文献+

治疗慢性免疫性血小板减少性紫癜新药:fostamatinib 被引量:1

A new drug in treatment of chronic immune thrombocytopenia purpura:fostamatinib
收藏 分享 导出
摘要 fostamatinib是一种由Rigel制药公司研发的脾酪氨酸激酶抑制剂。fostamatinib口服后转化为活性代谢产物R406,可抑制Fc活化受体和B细胞受体的信号转导。R406在体内约1.5 h达峰浓度,半衰期约为15 h。临床试验结果表明,与安慰剂相比, fostamatinib可有效提高并维持免疫性血小板减少性紫癜(ITP)患者的血小板计数,不良反应主要为腹泻和高血压。2018年4月,美国食品和药物管理局批准fostamatinib用于治疗慢性ITP且之前治疗效果不佳的成人患者。 Fostamatinib is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase(Syk),which was developed by Rigel Pharmaceuticals,Inc.After oral administration,fostamatinib was converted to R406,the major metabolite,inhibits signal transduction of Fc-activating receptors and B-cell receptor.R406 reached a peak at about 1.5 h in the body with a half-life of about 15 h.Clinical trials had shown that fostamatinib effectively increases and maintains platelet counts in patients with immune thrombocytopenia purpura(ITP) compared to placebo.The main adverse reactions were diarrhea and hypertension.The U.S.Food and Drug Administration approved fostamatinib for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment in April 2018.
作者 孙韬华 杜静 刘振胜 初晓 SUN Tao-hua;DU Jing;LIU Zhen-sheng;CHU Xiao(Department of Drug Clinical Trials,Qingdao Municipal Hospital,Qingdao SHANDONG 266011,China;Department of Pharmacy,Qingdao Municipal Hospital,Qingdao SHANDONG 266011,China)
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2019年第2期80-84,共5页 Chinese Journal of New Drugs and Clinical Remedies
关键词 fostamatinib 血小板减少 紫癜 血小板减少性 特发性 蛋白酪氨酸激酶类 临床研究 fostamatinib thrombopenia purpura,thrombocytopenic,idiopathic protein-tyrosine kinases clinical trial
作者简介 孙韬华,女,主管药师,硕士,主要从事新药的临床研究,E-mail:sun_taohua@126.com;初晓,女,主任药师,硕士,主要从事医院药学工作,E-mail:chenhaoyang2001@163.com
  • 相关文献

共引文献132

同被引文献11

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈